At ASCO, BioNTech Exhibits Encouraging Information for Drug That Led to $200M Deal
BioNTech paid $200 million to share within the improvement of an immunotherapy with potential benefits over a blockbuster Bristol Myers...
BioNTech paid $200 million to share within the improvement of an immunotherapy with potential benefits over a blockbuster Bristol Myers...